IM Cannabis Reports Third Quarter 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Should l Buy IMCC?
Source: PRnewswire
Q3 2025 Financial Performance: IM Cannabis Corp. reported consistent revenue of $13.9 million for Q3 2025, with a net loss of $3.9 million, significantly impacted by a $3.1 million impairment of goodwill and intangible assets.
Operational Challenges: The company faces potential negative impacts from expected regulatory changes in Germany, which may affect sales, and is undergoing a strategic review to explore new business activities for growth.
Financial Metrics: Gross profit decreased by 13% to $2.7 million, with a gross margin decline from 23% in Q3 2024 to 20% in Q3 2025, while total operating expenses rose by 68% to $6.9 million.
Liquidity and Assets: As of September 30, 2025, IM Cannabis had cash and restricted cash of $2.3 million, with total assets increasing to $44.3 million, primarily due to higher inventory and advances to suppliers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMCC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMCC
About IMCC
IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IM Cannabis Corp Plans to Acquire 51% of Blackaxe Technologies
- Strategic Expansion Plan: IM Cannabis Corp has announced a non-binding letter of intent to acquire 51% of Polish technology company Blackaxe, marking a strategic expansion into the defense and security technology sectors, aiming to leverage the growth potential of the global defense market.
- Surging Market Demand: The global defense market is rapidly expanding due to rising geopolitical tensions and the emergence of new threats, particularly the increasing demand for low-cost drones and advanced missile systems, and IMC's acquisition plan is designed to address this market need.
- Integration of Technological Advantages: Blackaxe specializes in satellite intelligence, imagery and AI analytics, and counter-drone solutions, utilizing advanced Israeli technologies to support governments and security agencies in addressing evolving aerial and intelligence threats, and IMC's acquisition will enhance its technological capabilities.
- Transaction Conditions and Risks: The proposed transaction is subject to due diligence, execution of definitive agreements, and regulatory approvals, with IMC facing industry regulations, market competition, and other uncertainties, indicating that the successful completion of the transaction remains at risk.
See More
IM Cannabis to Acquire 51% of Blackaxe Technologies
- Strategic Expansion Opportunity: IM Cannabis (IMCC) has signed a letter of intent to acquire 51% of Polish company Blackaxe Technologies, marking a potential entry into the defense and homeland security technology sectors, thereby enhancing its market competitiveness.
- Integration of Technical Expertise: Blackaxe specializes in advanced defense and intelligence solutions, and the acquisition will help IMCC integrate this technical expertise, thereby improving its capabilities and product offerings in related industries.
- Positive Market Reaction: Following the acquisition announcement, IMCC's stock rose 13.16% in premarket trading to $0.8955 per share, indicating investor optimism regarding the transaction.
- Future Growth Potential: By entering the defense and security technology market, IMCC not only diversifies its business model but also capitalizes on the growth potential in this sector, further driving its long-term strategic development.
See More
IM Cannabis to Acquire 51% Stake in Blackaxe Technologies
- Strategic Expansion: IM Cannabis Corp. has announced a non-binding letter of intent to acquire 51% of Blackaxe Technologies, marking a strategic move into the defense and security technology sectors, which is expected to enhance its market competitiveness.
- Growing Market Demand: The global defense and security market is rapidly expanding due to rising geopolitical tensions, and IMC's acquisition will enable it to leverage Blackaxe's advanced capabilities in satellite intelligence and counter-drone technologies to meet increasing market demands.
- Technological Integration Advantage: Blackaxe specializes in defense solutions based on advanced Israeli technologies, and IMC's acquisition will allow it to integrate these technologies, enhancing its business diversification and innovation capabilities beyond the medical cannabis sector.
- Transaction Conditions and Risks: The deal is subject to due diligence and regulatory approvals, and IMC faces multiple risks including industry regulations and market competition; successfully completing the transaction will have significant implications for its future growth.
See More
IM Cannabis Corp. Secures $2.17 Million in Debt Financing
- Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through a third-party loan agreement to address liquidity needs, enhancing financial flexibility amid operational challenges.
- First Note Details: The first note issued amounts to $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and has an 18-month maturity, reflecting the company's focus on effective debt management.
- Second Note Arrangement: The second note totals $632,911 with similar terms, including an 8% interest rate and identical repayment structure, further solidifying the company's financial foundation.
- Equity Conversion Rights: Both notes are convertible into common shares at a price of $1.47 or 90% of the lowest VWAP over 20 days, providing the company with a potential equity financing avenue.
See More
IM Cannabis Corp. Secures $2.17 Million in Debt Financing
- Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through an agreement with a third-party lender to address liquidity needs, thereby enhancing financial flexibility.
- First Note Details: The company issued a first note of $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and an 18-month maturity, reflecting a cautious approach to debt management.
- Second Note Issuance: The second note amounts to $632,911.50 with the same interest rate and maturity as the first, further solidifying the company's financial foundation to support operations and strategic initiatives.
- Equity Conversion Rights: Both notes are convertible into common shares, with the first note's conversion price set at $1.47 per share, ensuring the company maintains flexibility in future financing while providing potential value appreciation for investors.
See More
IM Cannabis Evaluates Strategic Entry into US Market Following Regulatory Changes
- Market Opportunity Assessment: IM Cannabis Corp. is evaluating strategic opportunities to enter the U.S. cannabis market in response to President Trump's December 18 executive order directing the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III, which is expected to open new revenue streams for the company.
- Advisory Services Collaboration: To advance its entry into the U.S. market, IM Cannabis has engaged SSC Advisors, who will provide customary financial advisory services, including strategic guidance on potential U.S. market entry and identifying prospective partners or acquirers, thereby enhancing the company's competitive positioning.
- Stock Price Reaction: In pre-market trading, IMCC shares rose by 9.42% to $1.51, reflecting investor optimism regarding the company's potential entry into the U.S. market, which may further drive the stock price upward.
- Strategic Significance: By entering the U.S. market, IM Cannabis can not only capitalize on the growing demand for medical cannabis but also enhance its brand influence and market share globally, aligning with the company's long-term growth strategy.
See More
IM Cannabis Corp Plans to Acquire 51% of Blackaxe Technologies
- Strategic Expansion Plan: IM Cannabis Corp has announced a non-binding letter of intent to acquire 51% of Polish technology company Blackaxe, marking a strategic expansion into the defense and security technology sectors, aiming to leverage the growth potential of the global defense market.
- Surging Market Demand: The global defense market is rapidly expanding due to rising geopolitical tensions and the emergence of new threats, particularly the increasing demand for low-cost drones and advanced missile systems, and IMC's acquisition plan is designed to address this market need.
- Integration of Technological Advantages: Blackaxe specializes in satellite intelligence, imagery and AI analytics, and counter-drone solutions, utilizing advanced Israeli technologies to support governments and security agencies in addressing evolving aerial and intelligence threats, and IMC's acquisition will enhance its technological capabilities.
- Transaction Conditions and Risks: The proposed transaction is subject to due diligence, execution of definitive agreements, and regulatory approvals, with IMC facing industry regulations, market competition, and other uncertainties, indicating that the successful completion of the transaction remains at risk.
See More
IM Cannabis to Acquire 51% of Blackaxe Technologies
- Strategic Expansion Opportunity: IM Cannabis (IMCC) has signed a letter of intent to acquire 51% of Polish company Blackaxe Technologies, marking a potential entry into the defense and homeland security technology sectors, thereby enhancing its market competitiveness.
- Integration of Technical Expertise: Blackaxe specializes in advanced defense and intelligence solutions, and the acquisition will help IMCC integrate this technical expertise, thereby improving its capabilities and product offerings in related industries.
- Positive Market Reaction: Following the acquisition announcement, IMCC's stock rose 13.16% in premarket trading to $0.8955 per share, indicating investor optimism regarding the transaction.
- Future Growth Potential: By entering the defense and security technology market, IMCC not only diversifies its business model but also capitalizes on the growth potential in this sector, further driving its long-term strategic development.
See More
IM Cannabis to Acquire 51% Stake in Blackaxe Technologies
- Strategic Expansion: IM Cannabis Corp. has announced a non-binding letter of intent to acquire 51% of Blackaxe Technologies, marking a strategic move into the defense and security technology sectors, which is expected to enhance its market competitiveness.
- Growing Market Demand: The global defense and security market is rapidly expanding due to rising geopolitical tensions, and IMC's acquisition will enable it to leverage Blackaxe's advanced capabilities in satellite intelligence and counter-drone technologies to meet increasing market demands.
- Technological Integration Advantage: Blackaxe specializes in defense solutions based on advanced Israeli technologies, and IMC's acquisition will allow it to integrate these technologies, enhancing its business diversification and innovation capabilities beyond the medical cannabis sector.
- Transaction Conditions and Risks: The deal is subject to due diligence and regulatory approvals, and IMC faces multiple risks including industry regulations and market competition; successfully completing the transaction will have significant implications for its future growth.
See More
IM Cannabis Corp. Secures $2.17 Million in Debt Financing
- Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through a third-party loan agreement to address liquidity needs, enhancing financial flexibility amid operational challenges.
- First Note Details: The first note issued amounts to $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and has an 18-month maturity, reflecting the company's focus on effective debt management.
- Second Note Arrangement: The second note totals $632,911 with similar terms, including an 8% interest rate and identical repayment structure, further solidifying the company's financial foundation.
- Equity Conversion Rights: Both notes are convertible into common shares at a price of $1.47 or 90% of the lowest VWAP over 20 days, providing the company with a potential equity financing avenue.
See More
IM Cannabis Corp. Secures $2.17 Million in Debt Financing
- Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through an agreement with a third-party lender to address liquidity needs, thereby enhancing financial flexibility.
- First Note Details: The company issued a first note of $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and an 18-month maturity, reflecting a cautious approach to debt management.
- Second Note Issuance: The second note amounts to $632,911.50 with the same interest rate and maturity as the first, further solidifying the company's financial foundation to support operations and strategic initiatives.
- Equity Conversion Rights: Both notes are convertible into common shares, with the first note's conversion price set at $1.47 per share, ensuring the company maintains flexibility in future financing while providing potential value appreciation for investors.
See More
IM Cannabis Evaluates Strategic Entry into US Market Following Regulatory Changes
- Market Opportunity Assessment: IM Cannabis Corp. is evaluating strategic opportunities to enter the U.S. cannabis market in response to President Trump's December 18 executive order directing the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III, which is expected to open new revenue streams for the company.
- Advisory Services Collaboration: To advance its entry into the U.S. market, IM Cannabis has engaged SSC Advisors, who will provide customary financial advisory services, including strategic guidance on potential U.S. market entry and identifying prospective partners or acquirers, thereby enhancing the company's competitive positioning.
- Stock Price Reaction: In pre-market trading, IMCC shares rose by 9.42% to $1.51, reflecting investor optimism regarding the company's potential entry into the U.S. market, which may further drive the stock price upward.
- Strategic Significance: By entering the U.S. market, IM Cannabis can not only capitalize on the growing demand for medical cannabis but also enhance its brand influence and market share globally, aligning with the company's long-term growth strategy.
See More
